Skip to main content
Search form
Search
Medicines for Malaria Venture
Developing antimalarials to save lives
Research & Development
MMV-supported projects
R&D areas of work
Next-generation medicines
Products for key populations
Working with regulators
Information for scientists
Call for proposals
TPPs & TCPs
Learning resources for discovery scientists
Project of the year award
Computational chemistry
Global health compound design webinars
R&D challenges
Access
Products & projects
Areas of work
Supporting introduction
Enhancing reach
Informing R&D
Gathering market intelligence
Product maps
Tool Kits
Injectable Artesunate tool kit
Artesunate rectal capsules tool kit
Seasonal Malaria Chemoprevention tool kit
The road to health impact
Access challenges
Partnering
Our partner network
The PDP model
Socially responsible agreements
Our clinical centre partners
Our donors
Current donors
Past donors
Donate to MMV
Our impact
Achievements
Real life stories
Better medicines for children
Malaria and COVID-19
About us
What we do
An overview of our work
Our strategic focus
Our history
People & governance
Staff bios
Staff map
Staff interviews
Board of Directors
MMV North America Board
Expert Scientific Advisory Committee
Access & Product Management Advisory Committee
Global Safety Board
Work with us
Jobs
RFPs/RFIs
MMV's internship programme
Policies
Diversity at MMV
Funding and expenditure
FAQs
Contact us
Malaria & medicines
Definitions and symptoms
Five species
Parasite lifecycle
Malaria facts & figures
Malaria treatment
History of antimalarials
Optimizing artemisinin production
Malaria online course
Newsroom
News & Press Releases
Films
Infographics
Interviews
Image slideshows
Publications
Audio
Events
MMV Open
Malaria
Libre
About Malaria
Libre
Participate in Malaria
Libre
Malaria
Libre
data repository
COVID Box
About the COVID Box
Request the COVID box
Supporting information
COVID Box terms and conditions
Pandemic Response Box
About the Pandemic Response Box
Request the Pandemic Response Box
Supporting information
Terms & conditions
Pathogen Box
About the Pathogen Box
Exploiting the Pathogen Box
Pathogen Box research
Supporting information
Terms & conditions
Malaria Box
About the Malaria Box
Malaria Box Research
Supporting information
Terms & conditions
Map of box orders
Follow-up guidelines
Open Source Drug Discovery
MMV Open Team
Contact us
Home
Newsroom
News & Press Releases
News & Press Releases
Filter
Category
All
News story
Press release
Topic
Access & product management
Donors
General
Open source
Partner
R&D
Search Terms
427 found
MMV launches the Pathogen Box
14 Dec 2015
Delivery of Coartem®
Dispersible
reaches a landmark of 300 million treatments
09 Dec 2015
WHO reports a ‘dramatic decline’ in malaria burden since 2000
09 Dec 2015
Ray Chambers entrusts Chairmanship of MMV to Per Wold-Olsen
04 Dec 2015
Pyramax® Granules becomes first paediatric antimalarial to receive EMA Article 58 positive scientific opinion
20 Nov 2015
European regulators grant Pyramax® a revised label
20 Nov 2015
2015 Social media malaria heroes announced
17 Nov 2015
MMV provides QIMR Berghofer AU$10 M for malaria drug development
08 Nov 2015
GHIT invests $10.7 million in malaria, TB, leishmaniasis and dengue research
05 Nov 2015
Eurartesim® (dihydroartemisinin-piperaquine) receives WHO prequalification
26 Oct 2015
New study details safety and efficacy of re-treatment with Pyramax®
23 Oct 2015
Comic books, science fiction and colour inspire two of ‘175 Faces of Chemistry’
09 Oct 2015
Nobel in Medicine awarded to parasitic disease drug pioneers
05 Oct 2015
Leader in the fight against malaria passes away
21 Sep 2015
WHO awards over $1 million to MMV’s ‘Exploiting the Pathogen Box’ project
19 Aug 2015
Call to nominate forward-thinking malaria heroes
13 Aug 2015
MMV welcomes launch of WHO
P. vivax
technical brief
29 Jul 2015
Pre-clinical assessment of exciting new malaria drug candidate published
16 Jul 2015
OZ439 recognized as a high-impact innovation to transform global health
16 Jul 2015
MMV wins Tim Berners-Lee’s Open Data Innovation Award
10 Jul 2015
New compound has the potential to treat malaria patients in a single dose
17 Jun 2015
GHIT, Takeda and MMV progress first-in-class antimalarial DSM265 to patient trials in Peruvian Amazon
05 Jun 2015
DNDi passes the ball to MMV
22 May 2015
MMV delivers statement at 68th World Health Assembly
19 May 2015
MMV joins the Asia Pacific Malaria Elimination Network (APMEN)
23 Apr 2015
MMV recognizes outstanding achievements of ISMO partners
09 Apr 2015
Merck Serono and MMV sign agreement to develop potential antimalarial therapy
01 Apr 2015
MMV welcomes continued Australian government support
24 Mar 2015
MMV awards challenge grants to seven Malaria Box recipients
06 Mar 2015
Japanese global health fund announces new investment in promising compounds for antimalarial drug discovery
05 Feb 2015
Independent Safety Monitoring Board assessment enables recruitment of 2-5 year olds into OZ439/PQP Phase IIb trial
20 Jan 2015
First Chair of MMV’s ESAC receives knighthood
12 Jan 2015
WHO’s much-awaited World Malaria Report reveals progress in the fight against malaria
10 Dec 2014
Three new roads leading to a common pathway
09 Dec 2014
MMV announces collaborations with Cipla and Strides
27 Nov 2014
Call for stories and ideas for GMAP2
20 Nov 2014
Child-friendly antimalarial reaches new landmark of 250 million treatments delivered
19 Nov 2014
MMV partner Prof. Luiz Carlos Dias receives Santander University Award
13 Nov 2014
300,000 vials of injectable artesunate delivered to Kenya and Nigeria
04 Nov 2014
Guilin’s SP+AQ added to WHO’s “List of Prequalified Products”
29 Oct 2014
Pyramax now registered in Cambodia
15 Oct 2014
NIH scientist Dr Martin John Rogers has passed away
09 Sep 2014
MMV organizes international malaria conference in Berlin
01 Jul 2014
MMV launches the Seasonal Malaria Chemoprevention Tool Kit
29 Apr 2014
GSK and MMV announce start of Phase III programme of tafenoquine
28 Apr 2014
MMV and Merck Serono join forces in antimalarial drug discovery
24 Feb 2014
MMV and partners call for compounds to fill the Pathogen Box
18 Feb 2014
Potential new antimalarial drug identified at the University of Dundee
06 Feb 2014
Takeda collaborates with MMV through GHIT Fund
24 Dec 2013
Breakthrough Therapy designation for potential new anti-relapse medicine for malaria
20 Dec 2013
Tafenoquine successfully completes Phase IIb clinical trials
19 Dec 2013
Rise in R&D funding could set the stage for malaria eradication
10 Dec 2013
State-of-the-art laboratory to study new antimalarials opens in Jakarta
10 Dec 2013
New antimalarial drug target identified
29 Nov 2013
Partners commit to bolstering open source research
27 Nov 2013
MMV signs MoU with Takeda and GHIT (Japan)
11 Nov 2013
MMV partner receives PLOS Accelerating Science Award
23 Oct 2013
First-ever drug compound developed on African soil, an antimalarial, to move to human trials
08 Oct 2013
Eurartesim® begins ‘real-life’ post African registration safety and effectiveness testing
03 Oct 2013
Campaign launched to help eliminate malaria deaths
23 Sep 2013
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
next ›
last »